Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP321 in Advanced Stage Solid Tumors
NCT03252938Phase 1Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2017
- Primary completion
- Sep 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of eftilagimod alpha in solid tumor, peritoneal carcinomatosis (PC), non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Feasibility rate at 12 weeks. Started Aug 2017; status: active, not recruiting.
02
Drugs
eftilagimod alpha
03
Conditions
solid tumorperitoneal carcinomatosis (PC)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03252938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252938.